Redfund Capital Corporation (CSE:LOAN) (Frankfurt: O3X4) (OTC: PNNRF) (Redfund or the “Company”) a merchant bank focused on financing medical cannabis, CBD and hemp companies is pleased to announce the launch of Dr. Klein CBD, and welcomes Dr. Robert Klein as a USA based advisor to the Company.
Dr. Klein CBD is launching a new line of pharma-grade infused CBD nutraceuticals, which include skin topicals and bath products. The Dr. Klein brand has a pain cream, healing stick, face moisturizer, infused serum plus the popular CBD infused bath bombs. The initial rollout will focus on the US chiropractic community and online consumer marketing, and then roll out globally in the fall.
“There are more than 60,000 doctors of chiropractic practicing in the United States. All 50 states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands recognize chiropractic as a health care profession and license the practice.” (American Chiropractic Association)
Dr. Robert Klein was raised in South Brunswick, New Jersey, received his Bachelor of Science in Human Biology and Doctor of Chiropractic degrees from the National College of Chiropractic in Lombard, Illinois. In 1995 Dr. Klein relocated and brought his award winning ways to Boca Raton, Florida. As a dedicated member of the Boca Raton community for over 23 years, Dr. Klein has been fortunate enough to be the official Chiropractor for Florida Atlantic University for 15 years. Dr. Klein has had the privilege of being on the Board of Directors for the Florida Chiropractic Association and has been the Palm Beach County delegate for the last 18 years, plus the past president of the local Palm Beach County Chiropractic Society and Keiser University’s Doctor of Chiropractic program board member, 2018, 2019.
“We are pleased to support Dr. Klein and the launch of the Dr. Klein CBD brand of pharma-grade CBD topicals and infused bathing products. These products will be laboratory tested prior to sales. We look forward to launching the Dr. Klein brand into Europe, South America and into Canada when regulation allows in the fall of 2019. Redfund will have an equity stake in the venture with further details to be released once definitive agreements are signed with Dr. Klein,” said Meris Kott, CEO.
“Nearly 7 percent of Americans are already using cannabidiol (CBD), placing the potential market opportunity for the much-hyped cannabis compound at $16 billion by 2025, according to a new analysis by Cowen & Co.” (Bloomberg LP)
According to an article written by Aaron Cadena a CBD enthusiast, passionate writer, and editor in chief at www.cbdorigin.com ― the CBD community’s leading digital publication and online knowledge base on May 8, 2019; “There has been a massive growth of awareness and surge in the retail sales of CBD, leading analyst to predict that the CBD market could reach a value of $22 billion by 2022. Research has revealed even more applications of CBD; Hemp-derived CBD was federally legalized under the 2018 Farm Bill. The FDA approved of a CBD-based oral solution called Epidolex; CBD products are now being sold online in stores across the country, including major retailers like 711, Sephora, and Neiman Marcus.”
Update: Jerry Hug announced as an advisor on February 7, 2019 is no longer an advisor to the Company.
About Redfund Capital
Redfund intends to provide debt and equity funding in the mid-to-late stages of a target company’s development, or in technologies that are developed and validated by revenues. The present focus of the merchant bank is on medical cannabis, hemp and CBD-related, healthcare-related target companies.
For further information please visit www.redfundcapital.com
For more information on Redfund Capital contact
Meris Kott CEO 604.484.8989
Further information about the Company is available on www.SEDAR.com under the Company’s profile.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, the Property, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
Both locations expand access to the state’s widest-ranging inventory of medical cannabis products for Central Florida patients
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of two brand-new Central Florida dispensaries. The new Clearwater and Tampa locations mark the Company’s 81 st and 82 nd nationwide, respectively, widening patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Philip Young, CEO and Director of Lobe, stated, “We are honored to welcome Bart to our Advisory Board. His first-hand experience on and off the field are tremendously valuable as we continue our research involving mild traumatic brain injuries and PTSD. These issues are prevalent in contact sports and we believe that athletes will play a prominent role in the continued acceptance of psychedelic medicines as legitimate treatment. We look forward to working with Bart as we seek to forge long-term strategic relationships.”
HempFusion Wellness Submits Novel Foods Dossier to the United Kingdom’s Regulatory Food Safety Agency
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that it has submitted its dossier to the United Kingdom’s Regulatory Food Safety Agency (the “FSA”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005322/en/